News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Capricor’s BLA for Deramiocel received Priority Review in March 2025
These medicines are essential in preventing RhD immunisation during pregnancy
Star Health Insurance is modernising its claims ecosystem to be future-ready
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Subscribe To Our Newsletter & Stay Updated
